These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 12734356)

  • 1. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.
    Dietrich PY; Le Gal FA; Dutoit V; Pittet MJ; Trautman L; Zippelius A; Cognet I; Widmer V; Walker PR; Michielin O; Guillaume P; Connerotte T; Jotereau F; Coulie PG; Romero P; Cerottini JC; Bonneville M; Valmori D
    J Immunol; 2003 May; 170(10):5103-9. PubMed ID: 12734356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity.
    Valmori D; Dutoit V; Schnuriger V; Quiquerez AL; Pittet MJ; Guillaume P; Rubio-Godoy V; Walker PR; Rimoldi D; Liénard D; Cerottini JC; Romero P; Dietrich PY
    J Immunol; 2002 Apr; 168(8):4231-40. PubMed ID: 11937585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
    Sensi M; Traversari C; Radrizzani M; Salvi S; Maccalli C; Mortarini R; Rivoltini L; Farina C; Nicolini G; Wölfel T
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5674-8. PubMed ID: 7777568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.
    Mandruzzato S; Rossi E; Bernardi F; Tosello V; Macino B; Basso G; Chiarion-Sileni V; Rossi CR; Montesco C; Zanovello P
    J Immunol; 2002 Oct; 169(7):4017-24. PubMed ID: 12244204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity.
    Colombetti S; Fagerberg T; Baumgärtner P; Chapatte L; Speiser DE; Rufer N; Michielin O; Lévy F
    J Immunol; 2006 Jun; 176(11):6560-7. PubMed ID: 16709813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
    Schaft N; Willemsen RA; de Vries J; Lankiewicz B; Essers BW; Gratama JW; Figdor CG; Bolhuis RL; Debets R; Adema GJ
    J Immunol; 2003 Feb; 170(4):2186-94. PubMed ID: 12574392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL.
    Rubio-Godoy V; Dutoit V; Zhao Y; Simon R; Guillaume P; Houghten R; Romero P; Cerottini JC; Pinilla C; Valmori D
    J Immunol; 2002 Nov; 169(10):5696-707. PubMed ID: 12421949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominant TCR-alpha requirements for a self antigen recognition in humans.
    Mantovani S; Palermo B; Garbelli S; Campanelli R; Robustelli Della Cuna G; Gennari R; Benvenuto F; Lantelme E; Giachino C
    J Immunol; 2002 Dec; 169(11):6253-60. PubMed ID: 12444131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires.
    Dietrich PY; Walker PR; Quiquerez AL; Perrin G; Dutoit V; Liénard D; Guillaume P; Cerottini JC; Romero P; Valmori D
    Cancer Res; 2001 Mar; 61(5):2047-54. PubMed ID: 11280765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A.
    Jäger E; Höhn H; Karbach J; Momburg F; Castelli C; Knuth A; Seliger B; Maeurer MJ
    Int J Cancer; 1999 Jun; 81(6):979-84. PubMed ID: 10362148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diversity and dominance among TCR recognizing HLA-A2.1+ influenza matrix peptide in human MHC class I transgenic mice.
    Man S; Ridge JP; Engelhard VH
    J Immunol; 1994 Nov; 153(10):4458-67. PubMed ID: 7963521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent contribution of T cell clonotypes with public TCR features to the chronic response against a dominant EBV-derived epitope: application to direct detection of their molecular imprint on the human peripheral T cell repertoire.
    Lim A; Trautmann L; Peyrat MA; Couedel C; Davodeau F; Romagné F; Kourilsky P; Bonneville M
    J Immunol; 2000 Aug; 165(4):2001-11. PubMed ID: 10925283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
    Merindol N; Grenier AJ; Caty M; Charrier E; Duval A; Duval M; Champagne MA; Soudeyns H
    J Immunol; 2010 Jul; 185(2):856-66. PubMed ID: 20543110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
    Wieckowski S; Baumgaertner P; Corthesy P; Voelter V; Romero P; Speiser DE; Rufer N
    J Immunol; 2009 Oct; 183(8):5397-406. PubMed ID: 19786555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.
    Serana F; Sottini A; Caimi L; Palermo B; Natali PG; Nisticò P; Imberti L
    J Transl Med; 2009 Mar; 7():21. PubMed ID: 19317896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens.
    Trautmann L; Labarrière N; Jotereau F; Karanikas V; Gervois N; Connerotte T; Coulie P; Bonneville M
    Eur J Immunol; 2002 Nov; 32(11):3181-90. PubMed ID: 12555663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Lejeune F; Speiser D; Rimoldi D; Cerundolo V; Dietrich PY; Cerottini JC; Romero P
    J Immunol; 2000 Jul; 165(1):533-8. PubMed ID: 10861093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual recognition of a human cytotoxic T-cell clone for melanoma antigens.
    Kubo H; Abe J; Obata F; Nakajima H; Tsunoda M; Ogawa A; Nakayama S; Beck Y; Kohsaka T; Darrow TL; Abdel-Wahab Z; Saida T; Takiguchi M
    Cancer Res; 1996 May; 56(10):2368-74. PubMed ID: 8625313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single amino acid replacements in an antigenic peptide are sufficient to alter the TCR V beta repertoire of the responding CD8+ cytotoxic lymphocyte population.
    Kalergis AM; Ono T; Wang F; DiLorenzo TP; Honda S; Nathenson SG
    J Immunol; 1999 Jun; 162(12):7263-70. PubMed ID: 10358174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.